Larkin, James

ROCK and JAK1 Signaling Cooperate to Control Actomyosin Contractility in Tumor Cells and Stroma

Sanz-Moreno, V., Gaggioli, C., Yeo, M., Albrengues, J., Wallberg, F., Viros, A., Hooper, S., Mitter, R., Féral, C. C., Cook, M., et al. (2011) · Cancer Cell

Cellular Mechanics and InteractionsCytokine Signaling Pathways and Interactions

Cited by 409

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

Diem, S., Kasenda, B., Spain, L., Martin-Liberal, J., Marconcini, R., Gore, M., & Larkin, J. (2016) · British Journal of Cancer

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 308

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial

Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F., Martignoni, M., Nathan, P., Powles, T., McDermott, D., Robbins, P. B., Chism, D. D., et al. (2018) · The Lancet Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 260

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials

Larkin, J., Lao, C. D., Urba, W. J., McDermott, D. F., Horak, C., Jiang, J., & Wolchok, J. D. (2015) · JAMA Oncology

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 223

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy

Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 222

Vessel Co-option Is Common in Human Lung Metastases and Mediates Resistance to Anti-angiogenic Therapy in Preclinical Lung Metastasis Models

Bridgeman, V. L., Vermeulen, P. B., Foo, S., Bilecz, A., Daley, F., Kostaras, E., Nathan, M. R., Wan, E., Frentzas, S., Schweiger, T., et al. (2017) · The Journal of Pathology

Angiogenesis and VEGF in CancerCancer Cells and Metastasis

Cited by 214

Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma

Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology

Cancer Immunotherapy and BiomarkersThyroid Disorders and Treatments

Cited by 190

SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy

Higham, C. E., Olsson-Brown, A., Carroll, P., Cooksley, T., Larkin, J., Lorigan, P., Morganstein, D., Trainer, P. J., & _, _. (2018) · Endocrine Connections

Cancer Immunotherapy and BiomarkersAdrenal Hormones and Disorders

Cited by 136

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

Gogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J., et al. (2021) · Annals of Oncology

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 102

Selection of metastasis competent subclones in the tumour interior

Zhao, Y., Fu, X., Lopez, J. I., Rowan, A., Au, L., Fendler, A., Hazell, S., Xu, H., Horswell, S., Shepherd, S. T. C., et al. (2021) · Nature Ecology & Evolution

Cancer Genomics and DiagnosticsCancer Cells and Metastasis

Cited by 95

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

Rini, B. I., Moslehi, J. J., Bonaca, M., Schmidinger, M., Albiges, L., Choueiri, T. K., Motzer, R. J., Atkins, M. B., Haanen, J., Mariani, M., et al. (2022) · Journal of Clinical Oncology

Renal cell carcinoma treatmentChemotherapy-induced cardiotoxicity and mitigation

Cited by 77

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Zimmer, L., Barlesi, F., Martinez-Garcia, M., Dieras, V., Schellens, J. H. M., Spano, J.-P., Middleton, M. R., Calvo, E., Paz-Ares, L., Larkin, J., et al. (2014) · Clinical Cancer Research

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 71

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

Gillessen, S., Murphy, L., James, N. D., Sachdeva, A., El-Taji, O., Abdel-Aty, H., Adler, A. I., Amos, C., Attard, G., Varughese, M., et al. (2025) · The Lancet Oncology

Metabolism, Diabetes, and CancerProstate Cancer Treatment and Research

Cited by 28

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., et al. (2021) · Annals of Oncology

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 21

Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.

Suarez Rodriguez, C., Larkin, J., Patel, P. M., Valderrama, B. P., Rodriguez-Vida, A., Glen, H., Thistlethwaite, F., Ralph, C., Srinivasan, G., Mendez-Vidal, M. J., et al. (2021) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 14

Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma

Larkin, J. M. G., Gordon, M. S., Thistlethwaite, F., Nathan, P. D., Rini, B. I., Martignoni, M., Shnaidman, M., Chiruzzi, C., Di Pietro, A., & Choueiri, T. K. (2016) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 13

Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)

Grob, J.-J., Schadendorf, D., Wagstaff, J., Márquez-Rodas, I., Lebbé, C., Ascierto, P. A., Hodi, F. S., Grossmann, K., Hassel, J. C., Walker, D., et al. (2017) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 8

Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.

Dearden, H. C., Au, L., Wang, D. Y., Zimmer, L., Eroglu, Z., Smith, J. L., Curvietto, M., Khoo, C., Atkinson, V., Lo, S., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2